NCT02365948 - A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Healthy Subjects

Interventions

BIOLOGICAL

Certolizumab Pegol

"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous injection"

OTHER

Placebo

"* Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringes~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection"

Trial Locations (1)

Unknown

1, Shanghai